Less to Hold - A Comparison of Bladder Toxicities (Side Effects) in Patients Undergoing Prostate Radiotherapy Between Patients Treated With Empty Bladder and Those on a Drinking Protocol.
1 other identifier
interventional
50
1 country
1
Brief Summary
Radical radiotherapy to the prostate is conventionally treated with a full bladder with the aim of minimising dose to the bladder and small bowel to prevent significant side effects. Tolerance of the bladder filling protocol varies depending on patients' baseline urinary function. It is not uncommon for some men to have "accidents" during treatment causing understandable distress. This can also extend the treatment time and cause knock on delays in the radiotherapy department. Several United Kingdom (UK) centres report treating with an empty bladder. The investigators carried out a feasibility study comparing treatment with full bladder to empty bladder to ascertain if the investigators can safely change our protocol to that of an empty bladder.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for not_applicable prostate-cancer
Started Mar 2017
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
March 1, 2017
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2018
CompletedStudy Completion
Last participant's last visit for all outcomes
January 25, 2019
CompletedFirst Submitted
Initial submission to the registry
January 29, 2019
CompletedFirst Posted
Study publicly available on registry
February 6, 2019
CompletedFebruary 6, 2019
February 1, 2019
1 year
January 29, 2019
February 5, 2019
Conditions
Outcome Measures
Primary Outcomes (1)
Change in IPSS score
IPSS - The International Prostate Symptom Score is a 7 question scale which assesses urinary toxicity. Each question is scored 0-5 totalling a maximum score of 35. A score of 0-7 correlates to mildly symptomatic; 8-19, moderately symptomatic; 20-35, severely symptomatic.
Baseline to end of treatment (4 weeks or 7 and a half weeks depending on radiotherapy schedule); to 6 week follow up; and to 1 year follow up.
Secondary Outcomes (2)
Change in LENT SOMA score
Baseline to end of treatment (4 weeks or 7 and a half weeks depending on radiotherapy schedule); to 6 week follow up; and to 1 year follow up.
Bowel and bladder DVH
At time of radiotherapy planning scan which happens at baseline, on day of randomisation.
Study Arms (2)
Empty Bladder
EXPERIMENTALEmpty bladder prior to treatment.
Full Bladder
OTHERConventional drinking protocol - 200ml water prior to treatment.
Interventions
Eligibility Criteria
You may qualify if:
- Prostate cancer receiving radical radiotherapy.
You may not qualify if:
- Not nodal disease.
- Not prostate bed radiotherapy.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Lancashire Teaching Hospitals NHS Foundation Trust
Preston, United Kingdom
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Alison Birtle
Lancashire Teaching Hospitals NHS Foundation Trust
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Masking Details
- Investigator masking for randomisation purposes only. Masking not possible for intervention whilst on treatment.
- Purpose
- OTHER
- Intervention Model
- PARALLEL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
January 29, 2019
First Posted
February 6, 2019
Study Start
March 1, 2017
Primary Completion
March 1, 2018
Study Completion
January 25, 2019
Last Updated
February 6, 2019
Record last verified: 2019-02
Data Sharing
- IPD Sharing
- Will not share